Incyte Corporation (BMV:INCY)

Mexico flag Mexico · Delayed Price · Currency is MXN
1,808.89
+75.89 (4.38%)
At close: Feb 13, 2026
Market Cap345.43B +19.0%
Revenue (ttm)92.56B +21.2%
Net Income23.16B +3,845.0%
EPS115.40 +4,173.3%
Shares Outn/a
PE Ratio14.91
Forward PE13.18
Dividendn/a
Ex-Dividend Daten/a
Volume6
Average Volume1,024
Open1,808.89
Previous Close1,733.00
Day's Range1,808.89 - 1,808.89
52-Week Range1,180.69 - 1,995.00
Betan/a
RSI57.18
Earnings DateFeb 10, 2026

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO fo... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1991
Employees 2,844
Stock Exchange Mexican Stock Exchange
Ticker Symbol INCY
Full Company Profile

Financial Performance

In 2025, Incyte's revenue was $5.14 billion, an increase of 21.22% compared to the previous year's $4.24 billion. Earnings were $1.29 billion, an increase of 3844.96%.

Financial numbers in USD Financial Statements